Construction Business Review Conferences

Boston, MA: The development of complement-targeted therapies is entering a new phase as researchers and biopharmaceutical companies expand beyond established pathways to explore broader clinical applications.

Scientific progress does not always provide a clear route from a promising asset to a viable development program.

CNS drug development depends increasingly on identifying biological signals that can support patient selection and provide earlier evidence of therapeutic activity.

Pharmaceutical supply chains must protect sensitive products while managing inventory and regulatory requirements across increasingly complex distribution networks.

Cell therapy for autoimmune disease is moving into a phase where early clinical promise must withstand broader tests of safety, durability and manufacturability.

Scientific breakthroughs reach patients only when research, investment and commercialization advance together. Biotechnology companies are placing greater emphasis on partnerships that support product development.

Cell and gene therapy is advancing through a combination of scientific innovation, translational research and cross-border collaboration.

Uniting 22 Countries, 900 Companies, and 2,300 Booths to Advance Global Biotechnology Collaboration.

The 17th World ADC San Diego Summit has announced its full 2026 agenda, bringing together over 170 expert speakers across seven dedicated content streams to advance the development of differentiated antibody-drug conjugates (ADCs) and drive impact.

As IVD regulatory pathways continue to ease and $60B+ in diagnostic deal-making reshaping partnerships, it is clear precision medicine has entered a defining new phase.